AHA again urges HHS to protect 340B program from drug companies’ actions

Sep 08, 2020 - 02:39 PM
AHA-OIG-letter

The AHA again expressed concern to the Department of Health and Human Services about recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to hospitals. 

While the Health Resources and Services Administration, which oversees the 340B program, is investigating these activities, AHA urged HHS to take “swift and decisive action to halt these pernicious tactics” to prevent other manufacturers from following suit.

“The drug companies are attempting to exploit for their financial benefit the current COVID-19 health care crisis,” AHA said. “As you are aware, hospitals throughout the nation are under severe stress by the need to prepare for, and/or care for, COVID-19 patients, while coping with the financial damages inflicted by the virus. Therefore, we urge you to act immediately against any drug manufacturer employing these pernicious tactics to ensure that 340B drugs are available and accessible to vulnerable communities.” Read the full letter here.

The AHA has engaged in numerous efforts urging the drug companies to cease these activities and have HHS take action to protect 340B hospitals. See the previous letters the AHA has sent on the issue:

Related News Articles

Headline
Blog: Putting 340B Program Growth in Context
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Blog
Putting 340B Program Growth in Context
Public
Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4…
Headline
AHA, others file suit to block unlawful 340B changes threatening patient care
The AHA, the Maine Hospital Association and four safety-net health systems from across the country Dec. 1 filed a lawsuit in the U.S. District…
Chairperson's File
Chair File: Leadership Dialogue — The Importance of the 340B Program with Aimee Kuhlman of the AHA and Paulette Davidson of Monument Health
Public
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Chairperson's File
Chair File: Protecting 340B and Access to Care
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…
Headline
HRSA approves 8 drug company plans for participation in 340B Rebate Model Pilot Program
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…